Plain-English translation of NCT05735704 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying whether a new blood test called HemaChip can detect early warning signs of blood cancers like multiple myeloma, lymphoma, and leukemia. The study will collect blood samples from people who have been diagnosed with these cancers, people who are at higher risk of developing them, and healthy volunteers. By analyzing these samples, the researchers hope to develop a tool that can catch these cancers much earlier, when treatment is often more effective.
Blood cancers are often detected late, when they are harder to treat. This study aims to create an early detection tool that could identify these diseases in their earliest stages, before symptoms appear, which could dramatically improve survival and quality of life.
You likely qualify if…
You likely don't qualify if…
If you are diagnosed with a blood cancer, you will give blood samples at regular intervals during your normal doctor visits and disease monitoring, following your standard treatment plan. If you are at risk or healthy, you will have an initial blood draw and periodic follow-up samples. All blood and plasma samples will be stored and analyzed to look for early disease markers. The study has three phases: first, researchers will study samples from a small group to develop the test; then they will test it on a larger group of patients and healthy volunteers; and finally, they will screen older adults and relatives of patients who have blood cancers.
AI-generated summary from trial data · Nov 17, 2026 · Not medical advice
Czechia
Greece
Israel
Lithuania